Tower Research Capital (TRC)’s Xenetic Biosciences XBIO Stock Holding History

Tower Research Capital (TRC)’s Portfolio XBIO Stock Details XBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.16K	Sell	806 -3,206	-80%	-$7.91K	﹤0.01%	4532
2025 Q4	$8.71K	Buy	+4,012	New	+$12.8K	﹤0.01%	3936
2024 Q4	–	Sell	-692	Closed	-$2.99K	–	6049
2024 Q3	$2.99K	Buy	+692	New	+$2.72K	﹤0.01%	4912
2024 Q2	–	Sell	-925	Closed	-$3.49K	–	6046
2024 Q1	$3.49K	Sell	925 -95	-9%	-$363	﹤0.01%	4855
2023 Q4	$3.52K	Sell	1,020 -364	-26%	-$1.28K	﹤0.01%	5070
2023 Q3	$6.78K	Buy	1,384 +763	+123%	+$3.19K	﹤0.01%	4557
2023 Q2	$2.04K	Sell	621 -514	-45%	-$1.91K	﹤0.01%	5264
2023 Q1	$5K	Hold	1,135	–	–	﹤0.01%	5002
2022 Q4	$3K	Sell	1,135 -34	-3%	-$150	﹤0.01%	5249
2022 Q3	$6K	Sell	1,169 -269	-19%	-$2.13K	﹤0.01%	5072
2022 Q2	$12K	Buy	1,438 +1,258	+699%	+$10.2K	﹤0.01%	4322
2022 Q1	$2K	Buy	180 +178	+8,900%	+$1.86K	﹤0.01%	5616
2021 Q4	$0	Sell	2 -299	-99%	-$4.77K	﹤0.01%	6623
2021 Q3	$6K	Buy	+301	New	+$8.2K	﹤0.01%	4781
2017 Q2	–	Sell	-8	Closed	-$5K	–	3532
2017 Q1	$5K	Buy	+8	New	+$4.25K	﹤0.01%	2236

Other funds holding XBIO

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

DWM

Darwin Wealth Management Tampa, Florida $365M AUM 22.69% 1-Year Est. Return

Tower Research Capital (TRC)'s XBIO Position: Q1 2026 in Review

Tower Research Capital (TRC) reduced its Xenetic Biosciences (XBIO) stake by 80% in Q1 2026, selling an estimated $7.91K and leaving 806 shares worth $2.16K. The position accounts for ﹤0.01% of the portfolio, ranked #4532.

Tower Research Capital (TRC) first reported a position in XBIO in Q1 2017 and has held it in 15 quarters since. The position peaked at $12K in Q2 2022. 6 funds tracked by Wall St. Rank hold XBIO as of Q1 2026.

Tower Research Capital (TRC) held 806 shares of Xenetic Biosciences worth $2.16K as of Q1 2026.
Tower Research Capital (TRC) sold 3,206 Xenetic Biosciences shares in Q1 2026, an estimated $7.91K.
Xenetic Biosciences made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #4532 holding.
Tower Research Capital (TRC) first reported a position in Xenetic Biosciences in Q1 2017 and has held it in 15 quarters since.
Tower Research Capital (TRC)'s Xenetic Biosciences position peaked at $12K in Q2 2022.
6 funds tracked by Wall St. Rank held Xenetic Biosciences as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.